SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 9.92% Stake in Treace Medical Concepts

Armistice Capital, LLC and Steven Boyd have disclosed a beneficial ownership of 9.92% in Treace Medical Concepts, Inc., holding 6,211,000 shares of common stock as of March 31, 2025.

Summary

• Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 6,211,000 shares of common stock in Treace Medical Concepts, Inc.
• This ownership represents 9.92% of the company's common stock outstanding.
• The percentage is calculated based on 62,618,725 shares outstanding as of February 19, 2025, as reported in the Issuer's Form 10-K filed on February 27, 2025.
• Armistice Capital, LLC, acting as the investment manager for Armistice Capital Master Fund Ltd., and Steven Boyd, as its managing member, share both voting and dispositive power over these 6,211,000 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Treace Medical Concepts, Inc.

Sentiment

Score: 6

Explanation: The disclosure of a significant 9.92% passive stake by a reputable investment firm like Armistice Capital can be viewed as a positive signal of confidence in the company's value, although the filing itself is purely factual.

Positives

• A significant stake of 9.92% held by an investment firm like Armistice Capital could signal confidence in Treace Medical Concepts, Inc.'s long-term prospects and valuation.
• The filing explicitly states that the shares are not held for the purpose of changing or influencing control, indicating a passive investment approach, which may reduce concerns about potential activist campaigns.

Future Outlook

NA

Industry Context

This filing indicates a significant investment by Armistice Capital, an investment firm, in a medical device company. Such investments are common in the healthcare sector, where specialized funds seek opportunities in growing or undervalued companies. The passive nature of this investment suggests a belief in the company's existing strategy rather than an intent to drive immediate operational changes.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by an institutional investor may provide a degree of confidence or validation regarding the company's valuation or prospects.

Key Dates

Keywords

Treace Medical Concepts, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Management, Passive Investment, Medical Devices